Please assess the completion status of the following clinical trial:

Trial Title: Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* The patient is male or female 18-75 years of age undergoing unilateral first metatarsal bunionectomy surgery~* Willing to give consent and able to understand the study procedures~* Female patients must be of non-childbearing potential or be practicing a highly effective contraception~* The patient must be willing to be housed in a healthcare facility and able to receive parenteral analgesia for at least 72 hours after surgery.~* The patient meets definition of American Society of Anesthesiologists (ASA) Physical Class 1, or 2.~Exclusion Criteria:~* Patient is not expected to receive a continuous infusion nerve block as described in the Post-Op anesthetic procedures protocol~* Patient is undergoing bilateral or revision bunionectomy surgery~* The patient has allergy or hypersensitivity (or is intolerant) to opioids or tramadol The patient has known physical dependence on opioids~* The patient has taken other prior/concurrent chronic medications that have not been at a stable dose for at least 2 weeks prior to screening~* The patient is taking herbal or dietary supplements or medications that are moderate or strong inhibitors of CYP2D6 or CYP3A4 or inducers of CYP3A4~* The patient has taken monoamine oxidase (MAO) inhibitors, trazodone, or cyclobenzaprine within 14 days prior to surgery~* The patient cannot be withdrawn from medications (at least 7 days prior to surgery) that may lower the seizure threshold (e.g. anti-psychotic agents, MAOI inhibitors) or which increase serotonergic tone (e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, triptans).~* The patient has a history of epilepsy, or is known to be susceptible to seizures~* The patient has a history of Long QT Syndrome or a relative with this condition~* The patient has expressed suicidal ideation or is considered to be at risk of suicide.~* The patient is morbidly obese (body mass index \[BMI\] ≥ 40 kg/m2) or has documented sleep apnea requiring pharmacological or device intervention.~* Clinically significant abnormalities in the judgement of the Investigator~* The patient was administered an investigational product within 30 days prior to Screening.~* The patient has previously participated in a clinical study with AVE-901.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AVE-901 50 mg (Type: ACTIVE_COMPARATOR): None
- AVE-901 25 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).